Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis

Published:2024 Issue:1 Volume:35 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Zhu Youwen¹^ORCID,Yang Qiuping²^ORCID,Liu Kun¹^ORCID,Cao Hui³^ORCID,Zhu Hong¹⁴^ORCID

Affiliation:

1. Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.

2. Department of Pathology, Tangshan Cancer Hospital, Tangshan, China.

3. Department of Oncology, Chenzhou First People’s Hospital, Chenzhou, China.

4. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

Funder

Clinical Research Project of Xiangya Hospital

Publisher

XMLink

Subject

Obstetrics and Gynecology,Oncology,General Medicine

Link

https://ejgo.org/pdf/10.3802/jgo.2024.35.e2

Reference40 articles.

1. Cancer statistics, 2022

2. Pan-cancer landscape of homologous recombination deficiency

3. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer

4. Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP